Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BVS vs NMTC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BVS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

BVS Overall Winner 6-Pillar Tally: BVS 5 – 1 NMTC Matrix Metrics: BVS 9 – 1 NMTC

As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BVS carries a Unified Composite Score of 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin), whereas NMTC carries 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin).

  • Technical & Structure Timing Caution: BVS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BVS vs NMTC
BVS NASDAQ Head-to-Head Winner
Bioventus Inc. Class A Common Stock
Surgical & Medical Instruments & Apparatus
$9.88
-0.7% 1D
Market Cap $681.3M
TTM Revenue $586M
Forward P/E 11.1x
Beta / 30D Vol 0.85β · 74% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 64.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.4%), weak momentum, RSI 29
RSI-14: 28.8 · SMA20: $11.75 · SMA50: $12.81
NMTC NASDAQ
NeuroOne Medical Technologies Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$0.65
-3.38% 1D
Market Cap $6.1M
TTM Revenue $12M
Forward P/E N/M
Beta / 30D Vol 1.55β · 105% Vol
Unified Composite Score
45.5 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 60.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -28.4%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $0.83 · SMA50: $1.03

6-Pillar Scorecard Institutional Category Breakdown (BVS 5 – 1 NMTC)

Columns: Metric · BVS · NMTC
1. Valuation Multiples BVS
Forward P/E 11.1x N/M
Trailing P/E 12.3x N/M
PEG Ratio 1.20x N/M
EV / Revenue 1.5x 0.3x
2. Growth & Scale BVS
Revenue Growth (YoY) +2.7% +16.3%
Earnings Growth (YoY) +69.7% +0.0%
TTM Revenue (USD) $586M $12M
Market Cap $681.3M $6.1M
3. Profitability & Quality BVS
Gross Margin 68.7% 23.0%
Operating Margin 10.1% -63.4%
Net Profit Margin 9.8% -59.7%
Return on Equity (ROE) 25.8% -124.7%
4. Balance Sheet & Cash Flow BVS
Cash Generation (TTM) $85M -$7.6M
Cash Flow Margin 14.5% -60.7%
Net Cash / Leverage $199M Net Debt (0.96x D/E) $2.6M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NMTC
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 448.1% (100th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat BVS
OpEx & R&D Intensity 58.6% of Rev ($343M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BVS (9) vs NMTC (1)
Institutional Metric BVS NMTC Criterion Row Edge
Market Capitalization
Scale
$681.3M $6.1M Larger Scale BVS
Trailing P/E Ratio
Valuation
12.3x N/M Lower Multiple BVS
Forward P/E Ratio
Valuation
11.1x N/M Lower Multiple BVS
Revenue Growth (YoY)
Growth
+2.7% +16.3% Higher Growth NMTC
Operating Margin (TTM)
Profitability
10.1% -63.4% Higher Margin BVS
Net Profit Margin
Profitability
9.8% -59.7% Higher Margin BVS
Return on Equity (ROE)
Capital Efficiency
25.8% -124.7% Higher ROE BVS
52-Week Range Position
Momentum
36% ($6–$16) 2% ($1–$5) Stronger Trend BVS
Beta / 30D Volatility
Risk Regime
0.85β · 74% Vol 1.55β · 105% Vol Lower Realized Risk BVS
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 45.5 / 100 (HOLD) Higher Composite BVS
Trailing 12M Revenue (USD)
Operating Scale
$586M $12M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.7% 23.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.20x PEG · 1.5x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$85M ($199M Net Debt (0.96x D/E)) -$7.6M ($2.6M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NMTC +0.85 pp
BVS: -34.31% · NMTC: -33.46%
3M Horizon BVS +40.0 pp
BVS: -29.53% · NMTC: -69.53%
6M Horizon BVS +88.8 pp
BVS: +6.47% · NMTC: -82.33%
1Y Horizon BVS +43.53 pp
BVS: +47.02% · NMTC: +3.49%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BVS Revenue NMTC Revenue BVS Op. Margin NMTC Op. Margin Margin Leader
FY2014 N/A $0M N/A -4646.1% NMTC
FY2019 $340M N/A 9.2% N/A BVS
FY2020 $320M N/A 6.6% N/A BVS
FY2021 $430M $0M 2.8% -5735.9% BVS
FY2022 $510M $0M -32.7% -5860.2% BVS
FY2023 $510M $0M -16.0% -612.3% BVS
FY2024 $570M $0M -2.7% -344.3% BVS
FY2025 $570M $10M 9.5% -46.5% BVS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BVS BREAKDOWN
76d in phase · OBV DISTRIBUTION
Current IV 448.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact BVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NMTC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMTC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BVS Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $681.3M market capitalization and 10.1% operating margin.
OpEx & R&D Reinvestment 58.6% of Rev ($343M)
90D Engineering Disclosures 0 Published
NMTC Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.1M market capitalization and -63.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BVS vs NMTC Key Questions & Quantitative Answers

As of Nov 20, 2026, Bioventus Inc. (BVS) is the stronger overall head-to-head candidate over NeuroOne Medical Technologies Corporation (NMTC) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BVS carries a Unified Composite Score of 46.2/100 (HOLD) at $9.88 (11.1x Forward P/E, 10.1% operating margin), whereas NMTC carries 45.5/100 (HOLD) at $0.65 (N/M Forward P/E, -63.4% operating margin). Technical & Structure Timing Caution: BVS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.8); meanwhile NMTC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BVS leads the Growth & Scale pillar: BVS posts +2.7% YoY revenue growth and +69.7% YoY earnings growth on $586M TTM revenue (68.7% gross margin, 10.1% operating margin), compared with NMTC at +16.3% YoY revenue growth and +0.0% YoY earnings growth on $12M TTM revenue (23.0% gross margin, -63.4% operating margin). Across the 8-period historical trajectory (FY2014 to FY2025), BVS cumulative revenue shifted +67.6% while NMTC shifted N/A. In operating R&D and SG&A reinvestment, BVS deploys 58.6% of Rev ($343M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NMTC.

BVS screens cheaper on headline valuation multiples. BVS trades at 11.1x Forward P/E, 12.3x Trailing P/E, 1.20x PEG, and 1.5x EV/Revenue (14.5% FCF margin), whereas NMTC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-60.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BVS (25.8% ROE) versus NMTC (-124.7% ROE) capital efficiency.

In options market volatility and institutional positioning, BVS carries 448.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.85β · 74% Vol realized risk). By comparison, NMTC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.55β · 105% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.